Author of

• 31891

  +

  EP1.03 - Biology (ID 193)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Biology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 31916

    +

    EP1.03-22 - Prognostic Value of Serum Inflammation Biomarkers in Early Stage Lung Adenocarcinoma (Now Available) (ID 1753)

    08:00 - 18:00  |  Author(s): Minjuan Hu
    • Abstract
    • Slides

    Background
    

    Non-small cell lung cancer is the main cause of cancer-related death worldwide, with a low 5-year survival rate even in early-stage. And adenocarcinoma accounts for the majority of all Non-small cell lung cancer cases. Biomarkers to identify prognosis of early stage lung cancer are needed. Increasing evidences indicate a relationship between inflammation and lung carcinogenesis. One of our previous studies found inflammation biomarkers, BLC and MDC, are significantly related with the risk of early stage lung cancer. The present study was performed to evaluated the value of inflammation biomarker in predicting the prognosis of early stage lung adenocarcinoma.

    Method
    

    Ten inflammation biomarkers were tested by Luminex bead-based assay in 157 patients with resected early-stage lung adenocarcinoma (IA-IIB) from whom serum samples were collected pre-surgery.

    Result
    

    A total of 152 early stage lung adenocarcinoma patients were analyzed in this study. The mean age (SD) of was 59.9 (9.4) years. 58.6% of them were females, and never smokers accounted for 84.0%. By TNM stage, 109 (71.7%) patients were at stage I and 43 (28.3%) at stage II. The median follow-up time was 60.6 months. Patients with higher MIG levels were at a 70% reduced risk of recurrence compared with patients with lower MIG levels (HR=0.3, 95% CI: 0.1–0.7, p=0.0035). As for BLC, patients with higher levels had the risk of recurrence decreased by 50% (HR=0.5, 95% CI: 0.3–0.9, p=0.031) compared with patients with lower levels. After the Bonferroni correction, only MIG was significantly associated with the recurrence risk of early stage lung adenocarcinoma. For overall survival (OS), patients with higher MIG levels were still have a reduced dead risk compared with the lower group (p=0.0065).

    Conclusion
    

    Our results demonstrate for the first time that pretreatment MIG level was identified as a protective factor for the prognosis of early stage lung adenocarcinoma.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.